MX347247B - Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad. - Google Patents
Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad.Info
- Publication number
- MX347247B MX347247B MX2012006199A MX2012006199A MX347247B MX 347247 B MX347247 B MX 347247B MX 2012006199 A MX2012006199 A MX 2012006199A MX 2012006199 A MX2012006199 A MX 2012006199A MX 347247 B MX347247 B MX 347247B
- Authority
- MX
- Mexico
- Prior art keywords
- agents
- treating disease
- regulatory
- antibodies
- activating
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención se refiere a métodos de criba para identificar moléculas capaces de ligar a CD4 y capaces de activar células T regulatorias CD4+CD25+. Además se proporcionan anticuerpos y fragmentos de anticuerpo capaces de activar células T regulatorias CD4+CD25+ y métodos y usos que involucran los anticuerpos y sus fragmentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0920944.6A GB0920944D0 (en) | 2009-11-30 | 2009-11-30 | Agents for treating disease |
PCT/EP2010/068579 WO2011064407A1 (en) | 2009-11-30 | 2010-11-30 | Agents for treating disease |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012006199A MX2012006199A (es) | 2012-06-19 |
MX347247B true MX347247B (es) | 2017-04-17 |
Family
ID=41572903
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012006199A MX347247B (es) | 2009-11-30 | 2010-11-30 | Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad. |
Country Status (17)
Country | Link |
---|---|
US (1) | US9995733B2 (es) |
EP (1) | EP2470902B1 (es) |
JP (1) | JP5959438B2 (es) |
KR (1) | KR101872746B1 (es) |
CN (1) | CN102687010B (es) |
AU (1) | AU2010323045B2 (es) |
BR (1) | BR112012012911A8 (es) |
CA (1) | CA2781836A1 (es) |
ES (1) | ES2643640T3 (es) |
GB (1) | GB0920944D0 (es) |
IL (1) | IL219956B (es) |
MX (1) | MX347247B (es) |
NZ (1) | NZ600889A (es) |
RU (1) | RU2598719C2 (es) |
SG (2) | SG10201407938TA (es) |
WO (1) | WO2011064407A1 (es) |
ZA (1) | ZA201204845B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
EP2471543A1 (en) * | 2010-12-02 | 2012-07-04 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Tolerance induction or immunosupression to prevent in particular Graft-versus-Host-Disease (GvHD) by short-term pre-incubation of transplanted cell suspensions, tissues or organs coated with ligands to cell surface molecules |
US20170232084A1 (en) | 2013-04-26 | 2017-08-17 | Enzo Biochem Inc. | Immune modulation for the treatment of age-related macular degeneration |
US20140322188A1 (en) | 2013-04-26 | 2014-10-30 | Enzo Biochem, Inc. | Tolerizing treatments for autoimmune disease |
GB201413899D0 (en) | 2014-08-06 | 2014-09-17 | Johnson Matthey Plc | Catalyst and use therof |
MA41943A (fr) * | 2015-04-24 | 2018-02-28 | Viiv Healthcare Uk No 5 Ltd | Polypeptides ciblant une fusion du vih |
US20180126021A1 (en) * | 2016-11-04 | 2018-05-10 | Covidien Lp | Sterilization system and method |
GB202017681D0 (en) | 2020-11-09 | 2020-12-23 | T Balance Therapeutics Gmbh | Anti-CD4 antibody or fragment thereof for medical use |
Family Cites Families (84)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT90657B (pt) | 1988-05-27 | 1995-03-01 | Ortho Pharma Corp | Processo para a preparacao de peptidos que bloqueiam a ligacao de hiv-1 a proteina cd4 receptora |
JPH0768273B2 (ja) * | 1988-12-02 | 1995-07-26 | カルピス食品工業株式会社 | 抗hivペプチド |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990013562A1 (en) | 1989-05-02 | 1990-11-15 | Genelabs Incorporated | Chemically modified cd4 peptide fragments having anti-retroviral properties |
GB8912497D0 (en) | 1989-05-31 | 1989-07-19 | Cobbold Stephen P | Monoclonal antibodies |
US5690933A (en) | 1989-05-31 | 1997-11-25 | Glaxo Wellcome Inc. | Monoclonal antibodies for inducing tolerance |
US20020099179A1 (en) | 1989-12-21 | 2002-07-25 | Linda K. Jolliffe | Cdr-grafted antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
HUT60768A (en) | 1990-03-16 | 1992-10-28 | Sandoz Ag | Process for producing cd25 fixing molecules |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
DE69126301T2 (de) | 1990-11-27 | 1998-01-02 | Biogen Inc | Hiv-induzierte synzytien blockierender anti-cd-4-antikörper |
US7192584B2 (en) | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
US6136310A (en) | 1991-07-25 | 2000-10-24 | Idec Pharmaceuticals Corporation | Recombinant anti-CD4 antibodies for human therapy |
JPH05244982A (ja) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | 擬人化b−b10 |
US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
IL101769A (en) | 1992-05-03 | 2007-02-11 | Yeda Res & Dev | Modulation of TNF receptor action |
US6270766B1 (en) | 1992-10-08 | 2001-08-07 | The Kennedy Institute Of Rheumatology | Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease |
WO1994008619A1 (en) | 1992-10-08 | 1994-04-28 | The Kennedy Institute Of Rheumatology | Treatment of autoimmune and inflammatory disorders |
PT614984E (pt) | 1993-03-05 | 2001-12-28 | Bayer Ag | Anticorpos humanos anti-tnf |
EP0631783A1 (en) | 1993-06-03 | 1995-01-04 | Mitsubishi Chemical Corporation | Antiviral combinations of 2',3'-di-deoxyribonucleosides with 6-benzyl-1-ethoxymethyl-5-substituted uracil derivatives |
JPH09510952A (ja) | 1993-10-06 | 1997-11-04 | ザ ケネディー インスティチュート オブ リューマトロジー | 自己免疫疾患および炎症性疾患の治療 |
US20020068057A1 (en) | 1994-03-10 | 2002-06-06 | Marc Feldmann | Treatment of autoimmune and inflammatory disorders |
JPH11505251A (ja) | 1995-05-18 | 1999-05-18 | オーソ・フアーマシユーチカル・コーポレーシヨン | 非枯渇性抗cd4抗体の使用による免疫寛容の誘導 |
CN103275221B (zh) | 1996-02-09 | 2016-08-17 | 艾伯维生物技术有限公司 | 结合人TNFα的人抗体 |
US20010056066A1 (en) | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
WO1998014211A1 (en) | 1996-10-01 | 1998-04-09 | Celltech Therapeutics Limited | Pharmaceutical products containing protein-tyrosine kinase inhibitors and anti-cd4 antibodies |
US6037454A (en) | 1996-11-27 | 2000-03-14 | Genentech, Inc. | Humanized anti-CD11a antibodies |
DE19722888A1 (de) | 1997-05-28 | 1998-12-03 | Thomas Prof Dr Huenig | Human-CD28 spezifische monoklonale Antikörper zur antigenunspezifischen Aktivierung von T-Lymphozyten |
AU3633000A (en) | 1999-03-26 | 2000-10-16 | Human Genome Sciences, Inc. | Neutrokine-alpha binding proteins and methods based thereon |
EP1194167B1 (en) | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target b-cells |
AU6941000A (en) * | 1999-08-27 | 2001-03-26 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use |
US7304127B2 (en) | 1999-08-27 | 2007-12-04 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use |
EP1289554A4 (en) | 2000-06-02 | 2004-05-26 | Univ Minnesota | IMMUNOTHERAPEUTIC PROCESS FOR PREVENTING REJECTION OF ISLAND CELLS |
MXPA03002262A (es) | 2000-09-18 | 2003-10-15 | Idec Pharma Corp | Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b. |
DE10050935A1 (de) | 2000-10-11 | 2002-05-02 | Tegenero Gmbh | Verwendung CD28 spezifischer monoklonaler Antikörper zur Stimulation von Blutzellen, welche kein CD28 tragen |
AP2003002828A0 (en) | 2001-01-16 | 2003-09-30 | Vascular Therapies Llc | Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts. |
WO2002072759A2 (en) | 2001-03-07 | 2002-09-19 | Children's Medical Center Corporation | Method to screen peptide display libraries using minicell display |
EP1241249A1 (en) | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
KR100861466B1 (ko) | 2001-04-24 | 2008-10-02 | 메르크 파텐트 게엠베하 | 항혈관형성제 및 TNFα를 이용한 병용 요법 |
US7541443B2 (en) | 2001-06-14 | 2009-06-02 | Tolerrx, Inc. | Anti-CD4 antibodies |
GB2376466A (en) | 2001-06-14 | 2002-12-18 | Mark Frewin | TRX1 antibody |
EP2345424A1 (en) | 2001-06-14 | 2011-07-20 | Tolerx, Inc | CD4-specific antibody TRX1 and uses therefor |
AU2002357427A1 (en) | 2001-12-04 | 2003-06-17 | Tegenero Ag | Peptide or protein containing a c'-d loop of the cd28 receptor family |
DE10212108A1 (de) | 2002-03-13 | 2003-10-02 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung |
DE10230223A1 (de) | 2002-07-04 | 2004-01-22 | Tegenero Ag | Mikropartikel mit CD28-spezifischen monoklonalen Antikörpern |
WO2004024097A2 (en) | 2002-09-16 | 2004-03-25 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US7388079B2 (en) * | 2002-11-27 | 2008-06-17 | The Regents Of The University Of California | Delivery of pharmaceutical agents via the human insulin receptor |
US7501494B2 (en) | 2003-01-15 | 2009-03-10 | United Biomedical, Inc. | Designed deimmunized monoclonal antibodies for protection against HIV exposure and treatment of HIV infection |
EP1460088A1 (en) * | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
ZA200507805B (en) | 2003-04-09 | 2006-12-27 | Genentech Inc | Therapy of autoimmune disease in a patient with an inadequate response to a TNF-alpha inhibitor |
GB0314461D0 (en) | 2003-06-20 | 2003-07-23 | Isis Innovation | Suppression of transplant rejection |
EP1658308A1 (en) | 2003-08-25 | 2006-05-24 | Pieris ProteoLab AG | Muteins of a bilin-binding protein with affinity for a given target |
EP1600164A3 (de) | 2003-09-22 | 2006-05-17 | TeGenero AG | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung |
DE10352900A1 (de) | 2003-11-11 | 2005-06-16 | Tegenero Ag | Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von B-CLL |
US20060002921A1 (en) | 2004-06-22 | 2006-01-05 | Tolerrx, Inc. | Optimized dosing with anti-CD4 antibodies for tolerance induction in primates |
EP1802659A2 (en) | 2004-07-02 | 2007-07-04 | Genentech, Inc. | Compositions and methods for treatment of non-hodgkin's lymphoma |
CN101031305A (zh) | 2004-09-29 | 2007-09-05 | 兴和株式会社 | 类风湿性关节炎的预防和/或治疗药物 |
ES2437571T3 (es) | 2004-11-11 | 2014-01-13 | Theramab Llc | Anticuerpos anti-CD28 superagonistas |
WO2006055077A2 (en) | 2004-11-12 | 2006-05-26 | The University Of North Carolina At Charlotte | Modulation of cd4+ t cell responses by a tick saliva protein, salp15 and polypeptides derived therefrom |
DE102004063494A1 (de) | 2004-12-23 | 2006-07-13 | Tegenero Ag | Antikörper |
JP4730733B2 (ja) | 2005-05-02 | 2011-07-20 | 国立大学法人京都大学 | 4型葉酸受容体の発現を指標とした制御性t細胞の検出方法、及び免疫賦活剤 |
EP2497496A3 (en) | 2005-07-11 | 2013-02-20 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
AU2006281803B9 (en) | 2005-08-18 | 2013-05-30 | Genmab A/S | Therapy with CD4 binding peptides and radiation |
NO345919B1 (no) | 2005-08-26 | 2021-10-18 | Roche Glycart Ag | Modifiserte antigen-bindende molekyler med endret celle-signaliseringsaktivitet |
PT1973950E (pt) * | 2006-01-05 | 2014-12-29 | Genentech Inc | Anticorpos anti-epbh4 e métodos que os utilizam |
EP2001510A4 (en) | 2006-03-16 | 2010-06-09 | Genentech Inc | METHODS OF TREATING LUPUS USING CD4 ANTIBODIES |
US8278421B2 (en) | 2006-03-20 | 2012-10-02 | Xoma Techolology Ltd. | Human antibodies specific for gastrin materials and methods |
US20090208471A1 (en) | 2006-04-07 | 2009-08-20 | Yun Theodore J | Isolation and Use of Human Regulatory T Cells |
BRPI0710826A2 (pt) | 2006-04-21 | 2011-08-23 | Novartis Ag | composições farmacêuticas de anticorpo anti-cd40 antagonista |
WO2007135684A2 (en) * | 2006-05-22 | 2007-11-29 | Hadasit Medical Research Services & Development Limited | Method of treatment of anti-cd4 autoimmunity |
US8557533B2 (en) | 2007-02-01 | 2013-10-15 | Helmut Jonuleit | Screening method for the identification of agents capable of activating CD4+CD25+ regulatory T-cells through interactions with the HIV-1 GP120 binding site on CD4 |
WO2008134046A1 (en) | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Potent, stable and non-immunosuppressive anti-cd4 antibodies |
SG190627A1 (en) | 2008-03-13 | 2013-06-28 | Biotest Ag | Agent for treating disease |
CN102027017A (zh) * | 2008-03-13 | 2011-04-20 | 生物测试股份公司 | 一种治疗疾病的试剂 |
JP5795167B2 (ja) | 2008-03-13 | 2015-10-14 | バイオテスト・アクチエンゲゼルシヤフト | 疾患治療剤 |
EP2101173A1 (en) | 2008-03-14 | 2009-09-16 | Vivalis | In vitro method to determine whether a drug candidate active against a target protein is active against a variant of said protein |
US8951793B2 (en) | 2008-08-21 | 2015-02-10 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Method of making an isolated population of FOXP3+ regulatory T cells |
ES2335381B1 (es) | 2008-09-24 | 2011-02-28 | Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron | Metodo in vitro y kit para el pronostico o prediccion de la respuestapor parte de pacientes con artritis reumatoide al tratamiento con agentes bloqueantes del factor tnfalfa. |
KR20110061630A (ko) | 2008-09-29 | 2011-06-09 | 바이오테스트 아게 | 질병 치료용 조성물 |
ES2351456B1 (es) | 2009-06-24 | 2011-11-28 | Fundacio Institut De Recerca De L'hospital Universitari Vall D'hebron | Metodo in vitro para el pronostico o prediccion de la respuesta por parte de pacientes con artritis reumatoide al tratamiento con agentes que reconocen el receptor de membrana cd20 de los linfocitos b |
JP5399219B2 (ja) | 2009-11-24 | 2014-01-29 | 株式会社ケイティーバイオ | 関節リウマチに対するヒト型抗TNFα抗体薬の薬効予測方法、及び薬効予測装置 |
WO2011158798A1 (ja) | 2010-06-14 | 2011-12-22 | 国立大学法人山口大学 | 乾癬治療効果の経過観察及び早期の予測方法並びにそれらに使用するキット |
-
2009
- 2009-11-30 GB GBGB0920944.6A patent/GB0920944D0/en not_active Ceased
-
2010
- 2010-11-30 CA CA2781836A patent/CA2781836A1/en not_active Abandoned
- 2010-11-30 WO PCT/EP2010/068579 patent/WO2011064407A1/en active Application Filing
- 2010-11-30 BR BR112012012911A patent/BR112012012911A8/pt not_active Application Discontinuation
- 2010-11-30 SG SG10201407938TA patent/SG10201407938TA/en unknown
- 2010-11-30 CN CN201080059459.9A patent/CN102687010B/zh active Active
- 2010-11-30 AU AU2010323045A patent/AU2010323045B2/en not_active Ceased
- 2010-11-30 NZ NZ600889A patent/NZ600889A/en not_active IP Right Cessation
- 2010-11-30 MX MX2012006199A patent/MX347247B/es active IP Right Grant
- 2010-11-30 EP EP10782326.2A patent/EP2470902B1/en active Active
- 2010-11-30 JP JP2012541473A patent/JP5959438B2/ja active Active
- 2010-11-30 RU RU2012127378/10A patent/RU2598719C2/ru not_active IP Right Cessation
- 2010-11-30 SG SG2012039442A patent/SG181117A1/en unknown
- 2010-11-30 ES ES10782326.2T patent/ES2643640T3/es active Active
- 2010-11-30 KR KR1020127016947A patent/KR101872746B1/ko active IP Right Grant
-
2012
- 2012-05-23 IL IL219956A patent/IL219956B/en not_active IP Right Cessation
- 2012-05-30 US US13/483,280 patent/US9995733B2/en active Active
- 2012-06-28 ZA ZA2012/04845A patent/ZA201204845B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CN102687010B (zh) | 2016-06-15 |
WO2011064407A1 (en) | 2011-06-03 |
JP2013511996A (ja) | 2013-04-11 |
EP2470902A1 (en) | 2012-07-04 |
RU2598719C2 (ru) | 2016-09-27 |
SG10201407938TA (en) | 2015-01-29 |
RU2012127378A (ru) | 2014-01-10 |
MX2012006199A (es) | 2012-06-19 |
US20130004513A1 (en) | 2013-01-03 |
KR20120102733A (ko) | 2012-09-18 |
AU2010323045A1 (en) | 2012-07-19 |
BR112012012911A8 (pt) | 2018-02-27 |
SG181117A1 (en) | 2012-07-30 |
CA2781836A1 (en) | 2011-06-03 |
EP2470902B1 (en) | 2017-07-19 |
IL219956B (en) | 2019-07-31 |
NZ600889A (en) | 2015-09-25 |
GB0920944D0 (en) | 2010-01-13 |
IL219956A0 (en) | 2012-07-31 |
CN102687010A (zh) | 2012-09-19 |
KR101872746B1 (ko) | 2018-06-29 |
AU2010323045B2 (en) | 2015-09-24 |
JP5959438B2 (ja) | 2016-08-02 |
BR112012012911A2 (pt) | 2016-10-25 |
US9995733B2 (en) | 2018-06-12 |
ES2643640T3 (es) | 2017-11-23 |
ZA201204845B (en) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12021550083A1 (en) | Human anti-tau antibodies | |
MX347247B (es) | Agentes capaces de la activación de células t regulatorias cd4+cd25+ y su uso en el tratamiento de enfermedad. | |
EP2566890A4 (en) | ANTI-PAI-1 ANTIBODIES AND METHOD FOR THEIR USE | |
MX369220B (es) | Moleculas que enlazan cd3 capaces de enlazar a cd3 humano y no humano. | |
NZ709353A (en) | Antibodies that bind il-4 and/or il-13 and their uses | |
GB201020995D0 (en) | Biological materials and uses thereof | |
CY1122978T1 (el) | Αντισωματα εναντι-vla-4 | |
MX345092B (es) | Anticuerpos anti-tau humanos,. | |
EA201390575A1 (ru) | Неантагонистические egfr-связывающие молекулы и их иммуноконъюгаты | |
EA201291039A1 (ru) | Антитела, связывающие cd27 человека, и их применение | |
TR201905909T4 (tr) | Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları. | |
MY161909A (en) | Anti-her3 antibodies and uses thereof | |
MY173839A (en) | Cd37-binding molecules and immunoconjugates thereof | |
AU2012335543A8 (en) | HER3 antibodies and uses thereof | |
MY164647A (en) | Cea antibodies | |
IN2014CN03042A (es) | ||
MX346500B (es) | Metodos y composiciones para inmunoterapia para enfermedad neural. | |
EA201590247A1 (ru) | Антитела к siglec-15 | |
MX2013011385A (es) | Moleculas de union a cd37 y sus inmunoconjugados. | |
WO2013013025A3 (en) | Anti-cxcr4 antibodies and methods of use | |
MX2014004326A (es) | Anticuerpos a cd1d. | |
MX343659B (es) | Proteínas de unión receptoras fc. | |
MX337203B (es) | Novedosas moleculas inhbidoras de jnk. | |
MX365387B (es) | Anticuerpos específicos de polipéptido amiloide de islote humano (hiapp) y sus usos. | |
EA201201526A1 (ru) | Способы лечения состояний, связанных с il-1b |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |